Transarterial radioembolization in hepatocellular carcinoma

Basit Öğe Kaydı
dc.authorscopusid7003405757
dc.authorscopusid57218767447
dc.authorscopusid56245802200
dc.contributor.authorKutlu R.
dc.contributor.authorKaratoprak S.
dc.contributor.authorKaradağ M.O.
dc.date.accessioned2024-08-04T20:03:50Z
dc.date.available2024-08-04T20:03:50Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractHepatocellular carcinoma (HCC) is the most common primary liver tumor and fourth most common cause of cancer-related deaths worldwide. For early-stage HCC patients, liver transplantation (LT) is the best choice because it reduces new HCC lesions due to the treatment of liver cirrhosis. But every patient is not a candidate for LT because of suitability of the patient (tumor size, macrovascular invasion, etc.) and availability of organ. For these unsuitable patients, there are nonsurgical treatment options such as transarterial embolization (TAE), transarterial chemoembolization (TACE), transarterial radioembolization (TARE), radiofrequency ablation (RFA), microwave ablation (MWA), and stereotactic body radiation therapy (SBRT). TARE is one of the interventional oncology procedures for unresectable HCC patients. It is a form of brachytherapy which allows localized radiotherapy to the liver tumors limiting the dose to the normal parenchyma. The isotope Yttrium-90 (90Y), embedded onto glass or resin microspheres, is given to the vessels which supply the tumor. Due to this selectivity of the procedure, TARE is a safe and effective treatment for unresectable HCC patients. There are advantages of TARE to the other locoregional therapies: It is an outpatient procedure; due to the minimal embolic effect, it may be performed to the cases with portal venous invasion which is contraindication of chemoembolization; and postembolization syndrome is seen rarely. Also, the main goal of TARE is downstaging the tumor for resection and liver transplantation and bridging to transplantation. It has an important role in every stages of HCC. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2021. All rights reserved.en_US
dc.identifier.doi10.1007/978-3-030-78737-0_9
dc.identifier.endpage169en_US
dc.identifier.isbn9783030787370
dc.identifier.isbn9783030787363
dc.identifier.scopus2-s2.0-85159691654en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage137en_US
dc.identifier.urihttps://doi.org/10.1007/978-3-030-78737-0_9
dc.identifier.urihttps://hdl.handle.net/11616/92139
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer International Publishingen_US
dc.relation.ispartofLiver Cancer in the Middle Easten_US
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatocellular carcinomaen_US
dc.subjectRadioembolizationen_US
dc.subjectTAREen_US
dc.titleTransarterial radioembolization in hepatocellular carcinomaen_US
dc.typeBook Chapteren_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu